Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Kipps on Frontline Therapies in CLL

Thomas J. Kipps, MD, PhD
Published: Tuesday, Oct 27, 2015



Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses use of frontline therapies for patients with chronic lymphocytic leukemia (CLL).

Though there are novel agents available in the frontline setting, there are some toxicities to be aware of, Kipps says. In a heterogenous disease such as CLL, some patients may have an indolent clinical disease course with minimal symptoms, while others rapidly progress and have disease-related complications. It is not always clear which disease course is most likely, he adds.

Oncologists should not prematurely treat patients with CLL due to the added toxicities. A common sense approach should still be used when treating patients, rather than relying on newer therapies, he adds. Patients who likely require treatment first experience rapid disease progression, limited marrow function, and immune-related dysfunctions.
 


Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses use of frontline therapies for patients with chronic lymphocytic leukemia (CLL).

Though there are novel agents available in the frontline setting, there are some toxicities to be aware of, Kipps says. In a heterogenous disease such as CLL, some patients may have an indolent clinical disease course with minimal symptoms, while others rapidly progress and have disease-related complications. It is not always clear which disease course is most likely, he adds.

Oncologists should not prematurely treat patients with CLL due to the added toxicities. A common sense approach should still be used when treating patients, rather than relying on newer therapies, he adds. Patients who likely require treatment first experience rapid disease progression, limited marrow function, and immune-related dysfunctions.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x